
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics PLC is demonstrating promising advancements with its Obe-cel therapy, which recently received a positive regulatory decision supported by strong efficacy and safety data from the pivotal FELIX study. The company aims to enhance its financial performance by achieving gross margins of 60-70% through increased manufacturing utilization and process enhancements, signaling a commitment to operational efficiency. Additionally, the favorable safety profile of Aucazyl positions it competitively in the market, potentially establishing it as the preferred CAR-T therapy for certain cancer indications.
Bears say
Autolus Therapeutics faces a challenging outlook due to anticipated flat sales for the third quarter of 2025, attributed to changes in CMS reimbursement policies, which may hinder revenue growth in the short term. Furthermore, the company's production of CAR-T therapeutics is projected to fall short of forecasts, raising concerns about its ability to meet market demands. Additionally, the presence of severe adverse events associated with its therapies, such as cytokine release syndrome and neurotoxicity, could further restrict market acceptance and patient utilization of Autolus’ products.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares